OncoPep, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: North Andover MA United States (2010)

Organization Overview

First Clinical Trial
2012
NCT01718899
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

OncoPep, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Smoldering Multiple Myeloma (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 10